Research Article

Association of GDF-15 and Syntax Score in Patient with Acute Myocardial Infarction

Shiqiang Liu, Xu Chen, Hua Wang, Bo Ming, Mingle Wu, Yongjie Wang, and Tao Liu

Department of Cardiothoracic Surgery, Nanchong Central Hospital, The Second Clinical College of North Sichuan Medical College, Nanchong, Sichuan 637900, China

Correspondence should be addressed to Tao Liu; nclt456@sina.com

Received 19 October 2018; Revised 16 January 2019; Accepted 13 February 2019; Published 5 March 2019

Academic Editor: Hangang Yu

Copyright © 2019 Shiqiang Liu et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Aims. GDF-15 is considered to be an important biomarker for cardiovascular events, but the differences in serum GDF-15 levels between acute myocardial infarction (AMI) patients and non-AMI patients warrant further investigation.

Methods. A cohort of 409 subjects was enrolled in the current study. The Syntax score was calculated from the baseline coronary angiography results by using online methods. Blood samples were obtained at the start of the study for an assessment of GDF-15 by using ELISA methods.

Results. Patients with AMI had significantly higher levels of serum GDF-15 (Wilcox test, \( P < 0.001 \)), Syntax scores (Wilcox test, \( P = 0.006 \)), and left ventricular ejection fractions (LVEF, Wilcox test, \( P < 0.001 \)). However, no significant differences were present among the other clinical characteristics. The logistical regression analysis indicated that serum GDF-15 levels (\( P=0.01534 \)) were independent predictors of non-AMI and AMI after adjusting for age, sex, smoking status, and LVEF.

Conclusions. Elevated serum levels of GDF-15 are independently associated with the risk of MI, and GDF-15 may serve as a protective factor for MI in the cardiovascular system.

1. Introduction

Myocardial infarction (MI), also known as a heart attack, occurs when blood flow decreases or is blocked from reaching a part of the heart, which then causes damage to the heart muscle [1]. In 2014, it was reported that the mortality rate due to cardiovascular diseases (CVD) was 295.63 per 100,000 people in rural areas and 261.99 per 100,000 people in urban areas [2]. National statistics have shown that the death rate due to acute myocardial infarction (AMI) sharply rises after the age of 40 years and that the mortality rate of AMI for patients who are over 85 years old is 95x that of the 40- to 45-year age group [3]. Therefore, normal patient populations who are older than 45 years old can be identified as individuals at high risk for MI and ischemic stroke [4]. Although a high incidence of MI occurs worldwide, the diagnosis of special types of MI has still posed a challenge for clinical practice. In the past several decades, cardiac markers (blood tests for heart muscle cell damage) have been mentioned and detected in patients with MI as assisting in the establishment of diagnoses, as well as in predicting future cardiovascular risks [5]. Numerous biomarkers have been used to determine the presence of cardiac muscle damage, such as troponins, creatine kinase-MB (CK-MB), or myoglobin [6]. Consequently, it has become crucial to validate the specific predictive values of these biomarkers in the specific situation of diagnosing MI before they are used as diagnostic or prognostic markers.

Growth differentiation factor 15 (GDF-15), a protein belonging to the transforming growth factor \( \beta \) (TGF-\( \beta \)) super family, was first identified as macrophage inhibitory cytokine-1, or MIC-1 [7]. The gene for this cytokine, which is located within chromosome 19p13.11, encodes a type of secreted ligand that binds various TGF-\( \beta \) receptors, thereby leading to recruitment and activation of SMAD family transcription factors that regulate gene expression [8]. In normal conditions, GDF-15 is expressed at lower levels in different organs and cell lines [9], but increased expression levels are associated with disease states, such as tissue hypoxia, inflammation, acute injury, and oxidative stress [10, 11]. The function of GDF-15 has not been fully illustrated to date; however, in animal models, it appears to have anti-inflammatory, antiapoptotic, or antihypertrophic effects for protecting
against cardiac injury [11, 12]. After the occurrence of MI, the levels of GDF-15 increase within hours in human heart tissue [13]. Investigations from Stergios et al. demonstrated that patients with MI and patients with adverse outcomes had higher GDF-15 levels compared with non-MI patients and that increased GDF-15 levels upon admission were associated with a hazard ratio of 2.1 for death or MI (95% CI: 1.67±2.63, P<0.001) [14]. Similarly, research from Alberto indicated that the 2-year outcomes of patients with acute coronary syndrome who developed major adverse cardiovascular events (MACE) had greater GDF-15 concentrations and syntax scores (P <0.001), compared to patients who did not have these conditions. Additionally, there was a positive but moderate correlation between GDF-15 and the syntax score (R=0.45, P<0.0001) [15]. However, whether GDF-15 is a diagnosis marker or a risk biomarker for AMI remains uncertain. In the current investigation, we aimed to test the hypothesis that serum GDF-15 levels can also be used as markers for distinguishing between AMI and non-AMI patients in a Han Chinese population. We also attempted to analyze the correlation between GDF-15 and the Syntax score for a risk prediction of AMI.

2. Materials and Methods

2.1. Samples. Four hundred nine samples were obtained from the Second Clinical College of North Sichuan Medical College during the time period of 2014 to 2017. All of the patients were assessed by trained cardiologists by using the 2014 ESC Guidelines for the Management of Acute Myocardial Infarction [6]. In addition, basic clinical characteristics (e.g., age, sex, height, body weight, and BMI), as well as blood and biochemical indicators, were recorded for the following analyses.

The AMI diagnostic criteria (according to the 2007 American Heart Association [AHA] unified definition) included the following: (1) patients who presented symptoms of acute chest pain, which is suggestive of an AMI; (2) myocardial necrosis markers (cTn) which were elevated above the reference, normal upper limit score of 99%, and were accompanied by at least one of several factors, including new ischemic changes (such as new ST-T changes or new left bundle branch blocks), electrocardiography (ECG) changes that are suggestive of a new pathogenesis of Q Wave formations, and imaging evidence (which suggests a newly viable myocardial loss or an abnormal wall motion), and (3) non-AMI diagnostic criteria which were present, such as coronary angiographies that showed no obvious stenotic lesions in the coronary arteries. The exclusion criteria were the following: congenital heart disease, a history of percutaneous coronary intervention within 3 months of the start of the study, pregnancy, a history of cardiac surgery, liver or kidney dysfunction, a history of malignancies, an acute pulmonary embolism, cerebral hemorrhage or cerebral infarction, acute infections, and a history of intravenous drug abuse.

This study was conducted with the approval of the ethics committee of the North Sichuan Medical College. The abilities and reasoning of the patients to understand and make rational decisions were included in the investigation. Subjects with traumatic brain injuries, color blindness, hearing impairments, and stuttering were excluded. All of the participants provided written informed consent.

2.2. Procedures. Peripheral blood (5 ml) was collected from all of the participants and was stored at −80°C until analysis. Serum GDF-15 (R&D Systems, Minneapolis, USA) levels were measured by using enzyme-linked immunosorbent assays (ELISAs). The concentrations of GDF-15 were higher than the range of detection and were subsequently diluted 10-fold with dilution buffer and reanalyzed in a portion of the samples.

The total Syntax score for each patient was calculated by using online methods (http://www.syntaxscore.com/calculator/start.htm) [16]. All of the evaluations were conducted by two cardiologists who were blinded to the study patient data.

2.3. Statistical. The clinical characteristics were presented as means ± SD (standard deviation), and all of the statistical analyses were conducted by using the R platform (http://www.R-project.org/). The categorical comparison tests for the disease traits (non-AMI and AMI) were analyzed by using the χ² test or the Wilcoxon test, as appropriate. The analysis of the correlation between GDF-15 and the Syntax score was performed with the Pearson test. A logistic regression analysis was used to assess the univariate associations between the clinical characteristics and the end point event. A Bonferroni correction was used to adjust the P values in order to reduce the incidence of type I errors due to multiple tests.

3. Results

3.1. Demographic Characteristics. Four hundred nine enrolled participations were included in the current investigation, and the baseline clinical characteristics are listed in Table 1. The average age of all of the patients was 56.59 ± 11.33 years old, and 229 of the 409 subjects had smoking habits. Most of the patients had high levels of triglycerides (mean ± SD: 1.82 ± 0.79; normal reference value: < 1.7 mmol/L) and glucose (mean ± SD: 6.39 ± 1.97; normal reference value: 3.9-6.1 μmol/L, under fasting conditions), which may be associated with the occurrence of acute cardiovascular events.

Within all of the recruited patients, 194 people experienced AMI, which included ST-segment and non-ST-segment elevation acute coronary syndrome (NSTEACS), whereas 215 people did not. Table 2 shows the comparison of the clinical characteristics between the patients with AMI and non-AMI. Patients with AMI had significantly higher levels of serum GDF-15 (Wilcoxon test, P <0.001), Syntax scores (Wilcoxon test, P =0.006), and left ventricular ejection fractions (LEV, Wilcoxon test, P <0.001). Other clinical, blood, and biochemical characteristics of the patients who were classified according to the presence or absence of AMI showed no significant differences.
Table 1: Baseline level of 409 samples with acute coronary syndrome.

| Variables                      | Values (Ratio/Mean ± SD) |
|--------------------------------|-------------------------|
| Age (years)                    | 56.59 ± 11.33           |
| Sex (Female/male)              | 229 (55.99%) / 180 (44.01%) |
| Smoker                         | 221 (54.03%)            |
| Total cholesterol (TC)         | 4.53 ± 1.02             |
| Triglycerides (TG)             | 1.82 ± 0.79             |
| High density lipoprotein cholesterol (HDL-C) | 1.19 ± 0.74 |
| Low density protein cholesterol (LDL-C) | 2.64 ± 0.68 |
| Serum creatinine (CR)          | 67.82 ± 17.52           |
| Glucose (GLU)                  | 6.39 ± 1.97             |
| Creatine kinase (CK)           | 665.38 ± 810.64         |
| White blood cell count (WBC)   | 8.88 ± 3.72             |
| Hemoglobin (Hb)                | 129.62 ± 16.74          |
| Platelet count (PLT)           | 236.91 ± 58.43          |
| Left ventricular ejection fraction (LVEF) | 50.82 ± 8.64 |
| Growth differentiation factor -15 (GDF-15) | 964.32 ± 352.16 |

Table 2: Comparison characterization between patients with non-AMI and AMI.

| Variables                      | Non-AMI (n=194)            | AMI (n=215)            | P value |
|--------------------------------|---------------------------|------------------------|---------|
| Age (Years, Mean ± SD)         | 59.14 ± 11.47             | 56.52 ± 10.14          | 0.169   |
| Sex (Female/male)              | 105/89                    | 124/91                 | 0.534*  |
| Smoking (Smoker/Non-smoker)    | 96/98                     | 115/100                | 0.478*  |
| Total cholesterol (TC)         | 4.85 ± 0.98               | 4.84 ± 0.86            | 0.934   |
| Triglycerides (TG)             | 1.69 ± 0.82               | 1.70 ± 0.74            | 0.472   |
| High density lipoprotein cholesterol (HDL-C) | 1.17 ± 0.25 |
| Low density protein cholesterol (LDL-C) | 2.53 ± 0.83 |
| Serum creatinine (CR)          | 70.54 ± 21.56             | 69.56 ± 16.99          | 0.369   |
| Glucose (GLU)                  | 6.23 ± 1.29               | 6.35 ± 1.65            | 0.447   |
| Creatine kinase (CK)           | 575.63 ± 784.59           | 769.7 ± 1011.05        | 0.163   |
| White blood cell count (WBC)   | 9.04 ± 3.88               | 8.69 ± 3.58            | 0.724   |
| Hemoglobin (Hb)                | 137.67 ± 19.76            | 140.98 ± 15.42         | 0.289   |
| Platelet count (PLT)           | 221.5 ± 50.13             | 242.99 ± 62.08         | 0.121   |
| Left ventricular ejection fraction (LVEF) | 44.36 ± 8.21 |
| Growth differentiation factor -15 (GDF-15) | 798.65 ± 197.05 |
| Syntax Score                   | 7.61 ± 8.19               | 13.31 ± 10.12          | 0.006   |

Wilcoxon or chi-sq test* according to data type.

3.2. Association between Serum GDF-15 Levels and Syntax Scores in Patients with Myocardial Infarction. A Pearson correlation was used to examine the association between GDF-15 levels and the Syntax scores in patients with MI. As shown in Figure 1, a moderate correlation existed between serum GDF-15 levels and the Syntax scores (Pearson correlation, R=0.567, P<0.001), and the regression line was depicted with an intercept of 0.342 and a slope of 0.01. From the logistical regression analysis, only serum GDF-15 levels (P =0.01534) were indicated as being independent predictors of non-AMI and AMI (Table 3).

Table 3: Logistical regression analysis of the myocardial infarction happening in 409 patients.

|                    | Estimate | Std. Error | Z value | Pr(>|z|) |
|--------------------|----------|------------|---------|---------|
| (Intercept)        | 1.45     | 0.065      | 21.99   | <0.001  |
| SYNTAX             | 0.0028   | 0.0045     | 0.637   | 0.5248  |
| GDF-15             | 0.0019   | 0.0007     | 1.485   | 0.0334  |
| Age                | -0.0147  | 0.038      | -0.386  | 0.67    |
| Sex                | 0.37     | 1.025      | 0.352   | 0.73    |
| Smoking            | -0.55748 | 1.098      | -0.508  | 0.512   |
| LVEF               | 0.232    | 0.067      | 3.507   | 0.056   |
4. Discussion

Biomarker testing in clinical practice has been viewed as a supplement to the diagnostic evaluation of patients who suffer from special types of diseases [17]. In the current investigation, it was confirmed that serum GDF-15 levels were correlated with the Syntax scores and that GDF-15 levels were also indicated as being independent predictors of non-AMI and AMI in a Han Chinese population. These results demonstrated that GDF-15 can be used as a confidential biomarker of AMI, rather than solely as a biomarker of cardiac stress.

GDF-15 is expressed at higher levels in placental, prostate, kidney, liver, and colon tissues under physiological conditions; however, in other organs, the expression levels of GDF-15 are low [9]. Similarly, with respect to cell lines, GDF-15 is expressed in endothelial cells, vascular smooth muscle cells, adipocytes, and macrophages. The function of GDF-15 is different in different tissues. For example, GDF-15 that is secreted in fat cells is mainly associated with the inhibition of the differentiation of adipocytes [18]. In activated macrophages, GDF-15 is highly expressed and present in serum that corresponds with various disease conditions [19]. However, under pathological conditions, GDF15 expression can be induced in response to diverse cellular stress signals, such as hypoxia/anoxia, inflammation, acute tissue injuries, and tumor processes. Various conditions, such as pregnancy, tumor, neuronal damage, erythropoiesis, and cardiological status, were accompanied by increasing GDF-15 levels. When considering the relationship between GDF-15 and cancer, this association has already been discussed to a high degree in other reviews [20]. GDF-15 is also suggested to be involved in the evolution of heart disease and to correspond with acute ischemia, ischemia-reperfusion injury, cardiac hypertrophy, and heart failure.

In 2002, a study by Brown et al. first examined the relationship between GDF-15 levels and cardiovascular events [21]. The results indicated that baseline plasma concentrations of GDF-15 in women were correlated with a higher degree of cardiovascular events (618 versus 538 pg/ml, P =0.0002), even after adjustments for classic cardiovascular risk factors, and that such effects were independent of traditional cardiovascular risk factors and were at least additive to the effects of C-reactive protein. Subsequently, GDF-15 was extensively investigated in relation to the development of heart failure, coronary heart disease, atrial fibrillation, and MI. In ventricular hypertrophy or hypertensive heart disease, it was suggested that the thickness of the posterior wall, serum norepinephrine levels, and the left ventricular mass were positively correlated with elevated levels of GDF-15, which demonstrated the possible cytoprotective effects of GDF-15 [22]. Wiklund et al. demonstrated that elevated serum GDF15 levels were predictors of overall mortality in the multivariate analysis and that this result was independent of age, BMI, and smoking status in a study of 815 Swedish males who were 46 to 80 years old and, in parallel, an independent cohort of 324 twins [23]. The potential mechanism of the relationship between GDF-15 levels and mortality still needs to be validated by more studies. However, the fact that serum GDF-15 levels can predict the progress and prognosis of cardiac events seems to have reached a consensus. Patients with non-ST-segment elevation myocardial infarction benefited from interventional therapy when serum GDF-15 levels were greater than 1200ng/L [24]. During the progress of coronary
heart disease, serum GDF-15 levels were closely related to the aggravation of the disease, which suggested a higher incidence of acute cardiac events. More importantly, it has been reported that GDF-15 may be an independent risk factor for AMI. Stergios et al. [14] measured the serum levels of GDF-15 for 1,818 enrolled patients with MI. Patients with MI had higher GDF-15 levels compared with non-MI patients (P < 0.001), and the increased GDF-15 levels upon admission were associated with a hazard ratio of 2.1 for death or MI (95% CI: 1.67 ± 2.65, P < 0.001) in a model that was adjusted for age and sex. The current investigation first compared the GDF-15 levels between patients with AMI and non-AMI. The results showed that serum levels of GDF-15 in the AMI group were significantly higher than the non-AMI group and that increases in GDF-15 levels can used as an independent predictor for AMI, even after adjustments for age, sex, smoking status, Syntax scores, and LVEF, which further indicated that GDF-15 may function as a monitoring index of myocardial infarction in certain application prospects.

Two limitations must be mentioned with respect to the current investigation. First, the sample size of this study was relatively small, which limited the power to detect the correlation between GDF-15 and the Syntax score. Further studies should include more samples. Second, we did not consider the possible interferences of confounding factors on the relationship between GDF-15 and AMI, which requires further investigation. Additionally, the potential mechanism underlying the association of GDF-15 with AMI has not been thoroughly elucidated to date.

5. Conclusions
Our current investigation suggested that elevated serum levels of GDF-15 are independently associated with MI and that GDF-15 may function as a protective factor for MI in the cardiovascular system.

Data Availability
The data used to support the findings of this study are available from the corresponding author upon request.

Conflicts of Interest
The authors declare that they have no conflicts of interest.

Authors’ Contributions
Shiqiang Liu performed the statistical analyses and manuscript preparing. Mr. Xu Chen, Hua Wang, Bo Ming, Mingle Wu, and Yongjie Wang were responsible for the data collection. Shiqiang Liu and Tao Liu devised such research and also revised manuscript for publishing. All the authors read and approved the final manuscript.

Acknowledgments
Current work was supported by the Municipal and University Cooperative Research Project of Nanchong (18SXHZ0475).

References
[1] T. Vos, C. Allen, M. Arora et al., “Global, regional, and national incidence, prevalence, and years lived with disability for 310 diseases and injuries, 1990–2015: a systematic analysis for the global burden of disease study 2015,” The Lancet, vol. 388, no. 10053, Article ID 19902015, pp. 1545–1602, 2016.
[2] C. Wei-Wei, G. Run-Lin, L. Li-Sheng et al., “China cardiovascular diseases report,” Journal of Geriatric Cardiology, vol. 14, no. 1, p. 1, 2017.
[3] S. Manzi, E. N. Meilahn, J. E. Rairie et al., “Age-specific incidence rates of myocardial infarction and angina in women with systemic lupus erythematosus: comparison with the Framingham study,” American Journal of Epidemiology, vol. 145, no. 5, pp. 408–415, 1997.
[4] H. S. Rosdy, I. I. El-Dosouky, and M. H. Soliman, “High-risk inferior myocardial infarction: Can speckle tracking predict proximal right coronary lesions?” Clinical Cardiology, vol. 41, no. 1, pp. 104–110, 2018.
[5] K. M. Eggers and B. Lindahl, “Prognostic biomarkers in acute coronary syndromes: risk stratification beyond cardiac troponins,” Current Cardiology Reports, vol. 19, no. 4, p. 29, 2017.
[6] E. A. Amsterdam, N. K. Wenger, R. G. Brindis et al., “2014 AHA/ACC guideline for the management of patients with Non-ST-Elevation acute coronary syndromes: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines,” Journal of the American College of Cardiology, vol. 64, no. 24, pp. e139–e228, 2014.
[7] M. R. Bootcov, A. R. Bauskin, S. M. Valenzuela et al., “MIC-1, a novel macrophage inhibitory cytokine, is a divergent member of the TGF-beta superfamily,” Proceedings of the National Academy of Sciences of the United States of America, vol. 94, no. 21, pp. 11514–11519, 1997.
[8] J. Xu, T. R. Kimball, J. N. Lorenz et al., “GDF15/MIC-1 functions as a protective and anti hypertrophic factor released from the myocardium in association with SMAD protein activation,” Circulation Research, vol. 98, no. 3, pp. 342–350, 2006.
[9] L. Fagerberg, B. M. Hallstrom, P. Oksvold et al., “Analysis of the human tissue-specific expression by genome-wide integration of transcriptomics and antibody-based proteomics,” Molecular & Cellular Proteomics: MCP, vol. 13, no. 2, pp. 397–406, 2014.
[10] J. Ago and J. Sadoshima, “GDF15, a cardioprotective TGF-β superfamily protein,” Circulation Research, vol. 98, no. 3, pp. 294–297, 2006.
[11] J. Heger, E. Schiegnitz, D. Von Waldthausen, M. M. Anwar, H. M. Piper, and G. Euler, “Growth differentiation factor 15 acts anti-apoptotic and pro-hypertrophic in adult cardiomyocytes,” Journal of Cellular Physiology, vol. 224, no. 1, pp. 120–126, 2010.
[12] S. Zhang, D. Dai, X. Wang et al., “Growth differentiation factor-15 predicts the prognosis of patients with acute coronary syndrome: a meta-analysis,” BMC Cardiovascular Disorders, vol. 16, no. 1, p. 82, 2016.
[13] S. Tzikas, L. Palapies, C. Bakogiannis et al., “GDF-15 predicts cardiovascular events in acute chest pain patients,” PLoS ONE, vol. 12, no. 8, p. e0182314, 2017.
[14] A. Dominguez-Rodriguez, P. Abreu-Gonzalez, P. Avanzas, and L. Consuegra-Sanchez, “Effect of serum growth differentiation factor-15 and the syntax score on 2-year outcomes in patients
with acute coronary syndrome,” American Journal of Cardiology, vol. 117, no. 10, pp. 1569–1574, 2016.

[16] G. Sianos, M. A. Morel, and A. P. Kappetein, “The SYNTAX score: an angiographic tool grading the complexity of coronary artery disease,” EuroIntervention, vol. 1, no. 2, pp. 219–227, 2005.

[17] R. R. J. van Kimmenade and J. L. Januzzi Jr., “Emerging biomarkers in heart failure,” Clinical Chemistry, vol. 58, no. 1, pp. 127–138, 2012.

[18] M. Yanagitai, T. Kitagawa, K. Okawa, H. Koyama, and T. Satoh, “Phenylenediamine derivatives induce GDF-15/MIC-1 and inhibit adipocyte differentiation of mouse 3T3-L1 Cells,” Biochemical and Biophysical Research Communications, vol. 417, no. 1, pp. 294–298, 2012.

[19] N. M. Ratnam, J. M. Peterson, E. E. Talbert et al., “NF-κB regulates GDF-15 to suppress macrophage surveillance during early tumor development,” The Journal of Clinical Investigation, vol. 127, no. 10, pp. 3796–3809, 2017.

[20] J. Corre, B. Hébraud, and P. Bourin, “Concise review: Growth differentiation factor 15 in pathology: A clinical role?” Stem Cells Translational Medicine, vol. 2, no. 12, pp. 946–952, 2013.

[21] D. A. Brown, S. N. Breit, J. Buring et al., “Concentration in plasma of macrophage inhibitory cytokine-1 and risk of cardiovascular events in women: a nested case-control study,” The Lancet, vol. 359, no. 9324, pp. 2159–2163, 2002.

[22] N. Nickel, D. Jonigk, T. Kempf et al., “GDF-15 is abundantly expressed in plexiform lesions in patients with pulmonary arterial hypertension and affects proliferation and apoptosis of pulmonary endothelial cells,” Respiratory Research, vol. 12, no. 1, p. 62, 2011.

[23] F. E. Wiklund, A. M. Bennet, P. K. E. Magnusson et al., “Macrophage inhibitory cytokine-1 (MIC-1/GDF15): a new marker of all-cause mortality,” Aging Cell, vol. 9, no. 6, pp. 1057–1064, 2010.

[24] K. C. Wollert, T. Kempf, B. Lagerqvist et al., “Growth differentiation factor 15 for risk stratification and selection of an invasive treatment strategy in non-ST-elevation acute coronary syndrome,” Circulation, vol. 116, no. 14, pp. 1540–1548, 2007.